Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Denali Therapeutics Inc. is currently managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 6 distinct examiners, which indicates a highly diversified prosecution environment. Each pending matter is reviewed by a different individual, requiring a broad strategy to address varying perspectives at the USPTO.
The portfolio spans 5 distinct art units, a count that is slightly lower than the number of examiners. This distribution suggests that some examiners are likely operating within the same art unit, potentially allowing for some administrative consistency. The busiest examiner, COLEMAN, BRENDA LIBBY, is responsible for 1 pending office action, reflecting an even workload distribution across the portfolio.
With the 6 pending office actions spread across 5 distinct art units, the company must navigate the specific guidelines of multiple specialized groups. The presence of many distinct examiners for the pending actions increases the variability of the prosecution process. Practitioners should prepare for unique examiner styles rather than a centralized negotiation strategy for the various pending matters currently under review.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 2 (33%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| LU, CHENG | 1 | 53.8% | +64.6% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| SHUPE, ELIZABETH A | 1 | 65.8% | +45.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17178595 | ANTI-HER2 POLYPEPTIDES AND METHODS OF USE THEREOF | SHUPE, ELIZABETH A | 79d overdue |
| 17797644 | METHODS FOR THE TREATMENT OF HUNTER SYNDROME | CHANDRA, GYAN | 37d overdue |
| 17296506 | METHODS FOR TREATING DYSREGULATED LIPID METABOLISM | AEDER, SEAN E | 15d overdue |
| 18276823 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | LU, CHENG | 46d |
| 18889058 | Kinase Inhibitors and Uses Thereof | COLEMAN, BRENDA LIBBY | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1624 | 1 |
| 1626 | 1 |
| 1674 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18889058 | Kinase Inhibitors and Uses Thereof | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18812872 | COMPOUNDS, COMPOSITIONS AND METHODS | JACKSON, SHAWQUIA | 1626 | §112 | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18276823 | ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF | LU, CHENG | 1642 | §102§103§112Other | Non-Final OA | 46d | Pending | Aug 10, 2023 |
| 17797644 | METHODS FOR THE TREATMENT OF HUNTER SYNDROME | CHANDRA, GYAN | 1674 | §103DP | Final Rejection | 37d overdue | Pending | Aug 04, 2022 |
| 17296506 | METHODS FOR TREATING DYSREGULATED LIPID METABOLISM | AEDER, SEAN E | 1642 | §103 | Final Rejection | 15d overdue | Pending | May 24, 2021 |
| 17178595 | ANTI-HER2 POLYPEPTIDES AND METHODS OF USE THEREOF | SHUPE, ELIZABETH A | 1643 | §103DP | Non-Final OA | 79d overdue | Pending | Feb 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDenali Therapeutics Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Brenda Libby Coleman has the most, with 1 of Denali Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
